Migraine Drugs Market

Migraine Drugs Market by Product Type (Acute migraine treatment, Preventive migraine treatment), Route of administration (Oral, Injection, and Others), and End User (Hospital pharmacies, Retail pharmacies, Online pharmacies) - Global Forecast to 2023

Report Code: UC 2003 May, 2023, by marketsandmarkets.com

Request for detailed table of content.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).

Manage preferences :

Select all
News-Letters with latest Market insights
Information & discussion on the relevant new products and services
Information & discussion on Market insights and Market information
Information & discussion on our events and conferences
Preferred modes for discussion
- Select all
- Email Phone Professional and social network (Linkedin, etc)

The global Migrane Drugs market is expected to reach USD 3.96 billion by 2023 from USD 1.95 million in 2018, growing at a CAGR of 15.2%. Increasing awareness about novel therapies, launch of Calcitonin Gene-related Peptide (CGRP), increasing incidence of migraines and launch of new drugs are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new drugs, thus propelling the market growth.

North America dominates the migraine drugs market with the North America accounted major market share in 2017. Established healthcare infrastructure; and increasing demand for preventive migraine treatment options are some of the major driving factors driving the growth of this market in North America. The Asian migraine drugs market is poised to grow at the highest CAGR during the forecast period owing to improving healthcare infrastructure and rising awareness about novel treatments among people in the region. The rising focus of prominent players on the Asian migraine drugs market is another factor driving its growth. Furthermore, emerging countries such as India and China provides immense growth opportunities to the migraine drug manufacturers.

Prominent players in the suture anchor devices market Abbott Laboratories (U.S.), Allergan (Ireland), Amgen (U.S.), GlaxoSmithKline (UK), Pfizer (U.S.), Eli Lilly (U.S.), Aegis Therapeutics, LLC. (U.S.), Johnson and Johnson (U.S.), and AstraZeneca PLC. (UK).

Scope of the Report

This research report covers the global Migraine Drugs market by method; product type; route of administration; end user; and geography.

Migraine Drugs Market, by Product Type

ACute migraine treatment
- ANALGESIC
- ERGOTAMINE
- TRIPTANS
Preventive migraine treatment
- BEta Blockers
- Anti-serotonergic drugs
- ANTIDEPRESSANTS
- Anti-convulsants
- Calcium Channel Blockers
- OTHERS